BRAIN Biotech AG Financial Results 9M 2024 / 25 | Strong Core Growth & BioIncubator Innovations
Investor Snapshot
- COMPANY
- BRAIN Biotech AG
- FORMAT
- Financial Results
- DURATION
- 11:40
- PUBLISHED
- September 2025
- LANGUAGE
- English
In 60 Seconds
Uncover BRAIN Biotech AG's FY-2022 financial performance, group structure, and future goals in this in-depth presentation by CFO Michael Schneiders. Discover the company's key financials, growth strategy, and commitment to sustainability.
September 30, 2025
11:40 
BRAIN Biotech AG Q1 2024/25: Key Takeaways
BRAIN Biotech 9M 2024/25 Financial Results Deep Dive
Presented by Michael Schneiders, CFO | seat11a.com
BRAIN Biotech Accelerates Growth in Core Business While Strengthening BioIncubator Pipeline
In the first nine months of fiscal year 2024/25, BRAIN Biotech AG delivered a robust operational performance marked by steady revenue growth in its core segment and significant progress in its innovation pipeline. CFO Michael Schneiders outlined the company’s dual focus: scaling its BRAIN Biocatalysts division and commercialising projects within the BRAIN BioIncubator—its innovation engine for biotech breakthroughs.
Solid Revenue Growth in Core Segment: BRAIN Biocatalysts
BRAIN Biocatalysts—the heart of BRAIN Biotech’s operations—continues to perform like a “Swiss army knife” of industrial biotech, demonstrating its versatility and adaptability. Revenue in this segment increased by 8.1% year-over-year in Q3, driven by strong product sales and increased utilization of large-scale fermenters, particularly at the Cardiff and US operations. While the baking ingredients sector faced some softness, other verticals remained resilient. The adjusted EBITDA margin continued to improve due to scale effects, a more favourable product mix, and disciplined cost management.
The division also stands out for its fully integrated biotech platform: from discovery and strain development to industrial-scale production and sales. BRAIN serves the full enzyme value chain, offering tailor-made solutions as a Contract Research Organisation (CRO) and Contract Manufacturing Organization (CMO/CDMO).
Innovation Engine: BRAIN BioIncubator
The BioIncubator division, which focuses on strategic participations and breakthrough biotech innovation, saw mixed performance in 9M 2024/25. While sales were softer due to the absence of milestone revenues from previous years and subdued order intake at AnalytiCon Discovery, significant strategic wins boosted the segment’s outlook. These wins include a strategic partnership with Corbion (Amsterdam-based sustainable ingredient leader) to commercialize “Perillic Active,” a natural antimicrobial for food preservation, and the successful consolidation of Breatec minorities, realizing a book gain of € 1.4 million.
One of the key factors contributing to our positive outlook is our strategic partnership with Corbion, a leading sustainable ingredient company based in Amsterdam. This partnership aims to commercialize “Perillic Active,” a natural antimicrobial for food preservation, which we believe will significantly enhance our product portfolio and market reach.
- Successful consolidation of Breatec minorities, realizing a book gain of €1.4 million.
- Strong cost control despite ongoing R&D investments and two months of Akribion Genomics integration.
- The company has €10.5 million in cash available, providing solid liquidity to drive further innovation.
Mid-Term Targets: Scaling with Precision
Reaffirming its long-term strategy, BRAIN Biotech aims to double revenues in BRAIN Biocatalysts to €100 million over the next five years, with an adjusted EBITDA margin of 15% and R&D investments of 4–6% of group sales. This growth will be driven by a combination of factors, including the commercialisation of milestones achieved by Pharvaris and genome-editing technologies (e.g., Akribion Therapeutics), which are expected to generate upside potential through milestone payments and royalty income. In the BioIncubator, the company’s focus will be on achieving commercialisation milestones and leveraging its strategic partnerships to fuel commercial upside.
Why Invest in BRAIN Biotech?
Michael Schneiders emphasizes BRAIN’s value proposition:
- Pioneering sustainable industrial biotechnology
- One of the few fully integrated enzyme specialists in Europe
- Positioned for high-margin, scalable growth
- Platform-based innovation with proven IP in CRISPR-Cas, enzyme libraries, and microbial strains
- Global partnerships with companies like Corbion and Pharvaris fuel commercial upside
The company is laser-focused on becoming a top-10 global enzyme player, driven by its robust biocatalyst business and an innovation-rich BioIncubator portfolio.
Chapters
- BRAIN Biotech can help to solve some of the world‘s greatest challenges
- Successful niche-player in research, development and production of enzyme
- BRAIN Biotech acts as a solutions provider across the entire enzyme value chain
- BRAINBiocatalysts – offering specialty products and tailor-made solutions
- BRAINBiocatalysts – significant room for growth in well over €2bn accessible market
- Key Messages 9M FY 2024/25
- Main Topics BRAINBioIncubator 9M FY 2024/25
- Financial Highlights 9M 2024/25 at a Glance
- Adjusted EBITDA
- Our Targets
- Why you should think about investing into BRAIN Biotech
Resources
Host
Share
T&C:
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG
Unlock the insights of top publicly listed companies with seat11a.com